1399PImpact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC). (23rd October 2018) - Peters, S; Shaw, A T; Besse, B; Felip, E; Solomon, B J; Soo, R A; Bearz, A; Gadgee, S M; Lin, C-C; Kao, S; Seto, T; Masters, E T; et al.